From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands.
Neurology. 2022 Mar 15;98(11):440-445. doi: 10.1212/WNL.0000000000013276. Epub 2022 Feb 2.
encodes the α1 subunit of the sodium-potassium ATPase, an electrogenic cation pump highly expressed in the nervous system. Pathogenic variants in other subunits of the same ATPase, encoded by or , are associated with syndromes such as hemiplegic migraine, dystonia, or cerebellar ataxia. Worldwide, only 16 families have been reported carrying pathogenic variants to date. Associated phenotypes are axonal neuropathies, spastic paraplegia, and hypomagnesemia with seizures and intellectual disability. By whole exome or genome sequencing, we identified 5 heterozygous variants, c.674A>G;p.Gln225Arg, c.1003G>T;p.Gly335Cys, c.1526G>A;p.Gly509Asp, c.2152G>A;p.Gly718Ser, and c.2768T>A;p.Phe923Tyr, in 5 unrelated children with intellectual disability, spasticity, and peripheral, motor predominant neuropathy. Additional features were sensory loss, sleep disturbances, and seizures. All variants occurred de novo and are absent from control populations (MAF GnomAD = 0). Affecting conserved amino acid residues and constrained regions, all variants have high pathogenicity prediction scores. In HEK cells transfected with ouabain-insensitive constructs, cell viability was significantly decreased in mutants after 72h treatment with the ATPase inhibitor ouabain, demonstrating loss of ATPase function. Replicating the haploinsufficiency mechanism of disease with a gene-specific assay provides pathogenicity information and increases certainty in variant interpretation. This study further expands the genotype-phenotype spectrum of .
编码钠钾 ATP 酶的 α1 亚基,这是一种在神经系统中高度表达的电致阳离子泵。同一 ATP 酶的其他亚基(由 或 编码)的致病性变体与偏头痛、肌张力障碍或小脑共济失调等综合征有关。迄今为止,全世界仅报道了 16 个携带致病性 变体的家族。相关表型为轴索性神经病、痉挛性截瘫和伴有癫痫发作和智力残疾的低镁血症。通过全外显子或基因组测序,我们在 5 名智力残疾、痉挛和周围性、以运动为主的神经病的非相关儿童中发现了 5 个杂合性 变体,c.674A>G;p.Gln225Arg、c.1003G>T;p.Gly335Cys、c.1526G>A;p.Gly509Asp、c.2152G>A;p.Gly718Ser 和 c.2768T>A;p.Phe923Tyr。此外,还存在感觉丧失、睡眠障碍和癫痫发作等症状。所有变体均为新生突变,且不存在于对照人群中(MAF GnomAD = 0)。影响保守氨基酸残基和约束区域,所有变体的致病性预测评分均较高。在转染无哇巴因敏感性 构建体的 HEK 细胞中,用 ATP 酶抑制剂哇巴因处理 72 小时后,突变体中的细胞活力显著降低,表明 ATP 酶功能丧失。通过基因特异性检测复制疾病的杂合不足机制,提供了致病性信息,并增加了对变体解释的确定性。本研究进一步扩展了 的基因型-表型谱。